您好,欢迎光临世界标品! 登录 注册(订药物标准品请用邮件联系我们)

SCITEK INTERNATIONAL (H.K.) LIMITED
Email: sciteck.hongkong@gmail.com
 

当前本网站药物产品种数共 8524 处方药 8148 非处方药 269 保健品/医疗用具 107

世界标品医药目录搜索(中英文):
世界各国官方药品目录搜索(英文):
世界标品医药知识搜索(中英文):

联系方式
国内客服电话:
国际免费电话:

咨询邮箱:
scimed.shanghai@shijiebiaopin.com
info@shijiebiaopin.com
pharmacy.shijiebiaopin1@gmail.com
pharmacy.shijiebiaopin2@gmail.com

  药店国别: 日本药房
产地国家: 日本
所属类别: 作用于呼吸系统药物->呼吸道感染
处方药:处方药
包装规格: 1克 10套
计价单位:
   
生产厂家英文名:
Taisho toyama
该药品相关信息网址1:
http://medical.taishotoyama.co.jp/data/tenp/htm/pnc-bag/tenpu.htm
原产地英文商品名:
PENTCILLIN ペントシリン静注用 1gバッグ 1g 10 kits
中文参考商品译名:
PENTCILLIN 1克 10套
原产地国家批准上市年份:
0000/00/00
英文适应病症1:
sepsis
英文适应病症2:
acute bronchitis
英文适应病症3:
cystitis
英文适应病症4:
cholecystitis
临床试验期:
完成
中文适应病症参考翻译1:
败血症
中文适应病症参考翻译2:
急性支气管炎
中文适应病症参考翻译3:
膀胱炎
中文适应病症参考翻译4:
胆囊炎
药品信息:
[功效或疗效] <适应的物种> 感性葡萄球菌,链球菌,肺炎链球菌,肠球菌,大肠杆菌,柠檬酸杆菌,肺炎克雷伯菌,肠杆菌属,沙雷菌属,变形杆菌属,摩根Morugani,普罗维登菌属,流感嗜血杆菌,铜绿假单胞菌对哌拉西林(一除普雷沃Bibia)菌,类杆菌,普氏菌 <适应症> ●败血症 ●继发感染急性支气管炎,肺炎,肺脓肿,脓胸,慢性呼吸道病 ●膀胱炎,肾盂肾炎 ●胆囊炎,胆管炎 ●前庭大腺炎,子宫内感染,子宫附件炎,子宫壁结缔组织炎 ●化脓性脑膜炎 [用法与用量] 哌拉西林钠时,成人中,它是静脉内分2-4次给药(效力)2~4克1天给药。 分2-4次给药(效价)静脉给药/公斤50~125毫克1天通常是儿童。 在成人中,此外,根据不同的条件,以严重感染或难治性,8克(效力),在儿童,静脉内增加200毫克至(效力)施用/公斤1月1日。 在给药时,在使用时,溶解在试剂盒中所含的特生理盐水溶液,和静脉内输注。 [用法] (慎用以下的患者服用。)1,仔细管理 <对哌拉西林钠注意事项> 患者过敏(1)头孢抗生素史 [因为有震荡看来,做得不够面试恐惧] 患者的构成容易发生支气管哮喘,皮疹,过敏反应荨麻疹的父母或兄弟姐妹(2)人 [患者的过敏体质容易引起过敏,可提供充足的采访] 肾功能衰竭患者(3)高级 [(参见“药代动力学”),它可以高的血药浓度持续] 患者接受肠外营养,患者全身情况较差或差的病人(4)口服 [患者通过饮食摄入谁也不能及时补充维生素K仔细观察,因为维生素K缺乏症状出现] 例(5)出血倾向 [有促进出血倾向的危险] [存在这样一种可能性,即血液浓度持续]患者(6)肝衰竭 [参看“管理,以5老人”](7)老年人 <关于盐水的注意事项> 例(1)心脏,循环系统功能障碍 [钠潴留和湿气有可能发生,(见“组成和性质”),这可能恶化水肿的症状等] 例(2)肾功能损害 [(参见“组成和性质”),这可能导致高钠血症的电解质异常等] 2,重要注意事项 代理本休克症状,过敏性休克样,因为没有办法肯定地预测的发生,您采取以下措施。 做得足够查问病史等(1)预。请注意,它也有可能确保检查过敏的抗生素的历史,等等。 在(2)的管理,始终震撼,它应该准备采取急救处理等。 这之后才管理(3)开始的任期将要结束,它被关在休息,患者的状态,进行充分观察。特别地,被给药开始后小心立即观察。 4,副作用 尚未进行过研究的临床试验中,如在本剂,成为明显的副作用发生率,但由于活性成分Pentoshirin注射,并且注射的肌肉内是相同的这种药物,Pentoshirin注射,肌内注射为我展示下面的调查结果。 批准的时间调查,148案件2,432例(其中实验室检查异常)的副作用为(6.09%)。此外,利用研究成果(1983年8月 - 1979年5月)批准后的四年里,396箱子19884例患者为(1.99%)。 在四年后的批准和核准的调查,副作用544案件22316例患者在所有情况下(2.44%)的观察,表达数为1,119。 120条评论175样皮疹(0.78%),152次助攻(GOT)增长(0.68%),143条评论ALT(GPT)升高(0.64%)(0.54%),主要是它由66白细胞减少为(0.30%),等。 应当指出,还包括副作用频率与它表达后批准是未知的此部分。 (1)严重副作用 1)休克,过敏反应 - (呼吸困难,皮肤瘙痒等)的症状,因为它可能会导致(小于0.1%),应仔细观察,政府应该停止,如果有任何异常的观察,来进行相应的操作。 2)中毒性表皮坏死松解症(莱尔综合征),Stevens-Johnson综合征(史蒂文斯 - 约翰逊综合征),因为它们可能(发生率不明)可能会发生,应仔细观察,政府应该停止,如果有任何异常发现,这是和应该采取适当的措施。 重症急性肾功能衰竭,间质性肾炎等。3)肾功能衰竭仔细监测,因为它们可能(发生率不明)出现,如检查,定期和管理是否异常,观察停药,并采取适当的措施。 4)全血细胞减少(发生率不明),粒细胞缺乏症(小于0.1%),血小板减少(少于0.1%),溶血性贫血,因为有时(往往是未知的)可能会出现,应仔细观察,发现异常中止给药时它们被识别,并适当的行动。 5)重度结肠炎有便血的伪膜性肠炎等。有时(发生率不明)可能会发生。停止和管理,如果立即腹泻腹痛,频繁出现,并应采取适当的措施。 6)间质性肺炎有发热,咳嗽,呼吸困难,胸部X线异常,嗜酸粒细胞增多等,PIE综合征等由于是(发生率不明)可能发生,如果有这样的症状出现,当局应停药,并采取适当措施如皮质类固醇激素。 7)横纹肌溶解症,因为它可能(发生率不明)可能会发生,政府应停药,如果肌肉疼痛,乏力,CK(CPK)增高,尿肌红蛋白和血压升高出现了,适当的通过进行治疗。此外,应谨慎急性肾功能衰竭的发展因横纹肌溶解症行使。 8)肝功能障碍,黄疸,因为它可能(小于0.1%),可能会发生,患者应仔细观察,政府应该停止,如果有任何异常的观察,采取相应的措施。 5,给予老人 老年人,(参见“药代动力学”)进行仔细施用,同时观察病人的状况是了解以下的,并要注意剂量和给药间隔时间。 副作用很可能是高表达的生理功能已经在一般(1)老年人降低。 有时有出血倾向,由于维生素K缺乏会出现在(2)老年人。 当局孕妇6油底壳或哺乳 只有当它确定该药物在怀孕期间的安全性尚未确定,孕妇和妇女被怀疑怀孕,治疗益处可能大于风险进行给药。 当局7个孩子,等等。 安全的低出生体重婴儿,新生儿尚未建立。 **对8的临床试验结果 通过这种药物的施用要注意,在尿糖检查通过还原方法临床试验,试剂的笃等,因为它可能呈现假阳性是很重要的。 注9,适用于 (1)给药途径:仅可以使用这个药物点滴静脉内给药。 (2)解散后: 在使用1)此药,你需要检查,它已经完全溶解。 要尽快2)溶解后使用。请注意,保存的(约5℃)的冰箱,即使需要强制保存并在24小时内使用。 通过掺混3)氨基糖苷类(妥布霉素,等等),等等导致的氨基糖苷类抗生素活性降低,并通过不同的途径各组合使用这种药物时施用。 该4)残余液体不以任何方式使用。 (3)静脉给药: 它可以被用来预热的溶液1)寒冷季节的体温。 2)静脉内给药,因为它们可能引起血管痛,静脉炎或血栓形成,减缓小心注射部位,注射法等,尽可能地喷射率。 注10,其他 根据(1)本药物的给药,进行血液测试,肝功能检查等定期是可取的。 据报道,这种药物的过敏症的症状的发病率是在囊性纤维化患者(2)外国更高。 已经报道(3)的组合,并延长维库溴铵的肌肉松弛作用。 [Effect or efficacy] Staphylococcus sensibility, Streptococcus, Streptococcus pneumoniae, Enterococcus spp, Escherichia coli, Citrobacter, Klebsiella pneumoniae, Enterobacter, Serratia, Proteus, Morganella Morugani, Providencia spp, Haemophilus influenzae, Pseudomonas aeruginosa to piperacillin (I except Prevotella Bibia) bacteria, Bacteroides, Prevotella ● sepsis ● secondary infection acute bronchitis, pneumonia, lung abscess, empyema, chronic respiratory disease ● cystitis, pyelonephritis ● cholecystitis, cholangitis ● bartholinitis, intrauterine infection, uterine adnexitis, uterus parietal connective tissue inflammation ● purulent meningitis [Usage and dosage] As piperacillin sodium, in the adult, it is administered intravenously in 2-4 divided doses (potency) 2 ~ 4g 1 day. Administered intravenously in 2-4 divided doses (potency) / kg 50 ~ 125mg 1 day usually children. In addition, depending on the condition to severe infection or refractory, 8g (potency), in children, is administered intravenously in increasing 200mg to (potency) / kg 1 January day in adults. Upon administration, on use, is dissolved in the JP saline solution contained in the kit, and infused intravenously. [Usage] (Be administered with caution in the following patients.) 1. Careful Administration Patients with a history of hypersensitivity to (1) cephem antibiotics [because there is a fear that the shock appears, doing enough interview] Patients with a constitution prone bronchial asthma, rashes, allergic reactions urticaria parents or siblings (2) person [patients with allergic diathesis are easily cause hypersensitivity, which provide adequate interview] Patients with renal failure (3) advanced [(see the section "pharmacokinetics"), which can high blood levels persist] Patients receiving parenteral nutrition, patients with poor general condition or patients with poor (4) oral ingestion [be carefully observed in patients who can not replenish the vitamin K by dietary intake, because there is that vitamin K deficiency symptoms appear] Patients with (5) bleeding diathesis [there is a risk that promotes bleeding tendency] [There is a possibility that the blood concentration is sustained] Patients with (6) liver failure [See the section "administration to 5. elderly"] (7) the elderly Patients with (1) the heart, the circulatory system dysfunction [sodium retention and moisture is likely to occur, (see the "composition and properties") that may worsen the symptoms of edema, etc.] Patients with (2) renal impairment [(see the section "composition and properties") which may lead to electrolyte abnormalities of hypernatremia, etc.] 2. Important Precautions Agent according to the present symptoms shock, anaphylaxis-like because there is no way of predicting with certainty the occurrence of, that you take the following measures. Be made sufficiently questioning medical history, etc. (1) Pre. Note that it is also possible to be sure to check history of allergy with antibiotics, etc.. Upon (2) administration, always shock and that it should be prepared to take a first aid treatment for such. That until the end of the administration after (3) the start of the administration, it was kept in a state of rest the patient, to carry out a sufficient observation. In particular, be observed carefully immediately after the start of administration. 4. side effects Has not been conducted research clinical trials, such as in the present agent, become apparent side effects incidence, but because the active ingredient Pentoshirin for injection, and intramuscular injection for are the same this drug, Pentoshirin for injection, the intramuscular injection for I show below survey results. A survey of the time of approval, 148 cases of 2,432 patients (including abnormal laboratory values) side effects was (6.09%). In addition, the use of research results (August 1983 - May 1979) four years after approval, 396 cases of 19,884 patients it was (1.99%). In the investigation of the four-year post-approval and approval, side effects observed in 544 cases of 22,316 patients in all cases (2.44%), expression number was 1,119. 120 reviews 175 fever rash (0.78%), 152 AST (GOT) increase (0.68%), 143 reviews ALT (GPT) increase (0.64%) (0.54%), which consist primarily of, 66 leukopenia was (0.30%), and the like. It should be noted, also includes side effects frequency with which it was expressed after approval is unknown in this section. (1) serious side effects 1) shock, anaphylaxis - (difficulty breathing, itching, etc.) like symptoms because it may cause (less than 0.1%), should be carefully observed, administration should be discontinued and if any abnormalities are observed, appropriate action be performed. 2) toxic epidermal necrolysis (Lyell syndrome), Stevens-Johnson syndrome (Stevens - Johnson syndrome) because they may (incidence unknown) may occur, should be carefully observed, administration should be discontinued and if any abnormality is observed that it was, and appropriate measures should be taken. 3) renal failure with severe acute renal failure, interstitial nephritis, etc. carefully monitored because they may (incidence unknown) appears, such as inspected on a regular basis, and administration if abnormalities are observed be discontinued, and appropriate measures should be taken. 4) pancytopenia (incidence unknown) , agranulocytosis (less than 0.1%) , thrombocytopenia (less than 0.1%) , hemolytic anemia because sometimes (often unknown) may appear, should be carefully observed, abnormal be discontinued administration when they are recognized, and appropriate action. 5) colitis severe with bloody stool pseudomembranous colitis, etc. Sometimes (incidence unknown) may occur. Be discontinued and administration immediately if diarrhea abdominal pain, frequent appeared, and appropriate measures should be taken. 6) interstitial pneumonia with fever, cough, dyspnea, chest X-ray abnormalities, etc. eosinophilia, PIE syndrome, etc. Because there is that (incidence unknown) may occur, if such symptoms appeared that the administration should be discontinued and appropriate measures such as administration of corticosteroids. 7) rhabdomyolysis because it may (incidence unknown) may occur, administration should be discontinued and if the muscle pain, weakness, CK (CPK) increased, urine myoglobin and elevated blood appeared, and appropriate By performing the treatment. In addition, caution should be exercised in the development of acute renal failure due to rhabdomyolysis. 8) liver dysfunction, jaundice because it may (less than 0.1%) may occur, patients should be carefully observed, administration should be discontinued and if any abnormalities are observed, take appropriate measures. 5. administration to elderly The elderly, (see the "pharmacokinetics") be administered carefully while observing the condition of the patient is aware of the following, and to pay attention to dose and dosing interval. Side effects is likely to be highly expressed that the physiological function has decreased in general (1) the elderly. Sometimes bleeding tendency due to vitamin K deficiency appears in (2) the elderly. Administration to pregnant women 6.-sump or Lactation Be administered only when it is determined that the safety of this drug during pregnancy has not been established, in pregnant women and women suspected of being pregnant, therapeutic benefit may outweigh the risk. Administration to 7 children, etc. Safety low-birth-weight infants, neonates has not been established. ** Effect on 8. Clinical test results It is important to note by the administration of this drug, in urine sugar inspection by the reduction method clinic test, Benedict of reagents and the like, because it may exhibit a false positive. Note 9. apply on (1) the route of administration: this drug be used only to drip intravenous administration. (2) after dissolution: In use of 1) this drug, you need to check that it has completely dissolved. Be used as soon as possible 2) after dissolution. Note that it saved (about 5 ℃) refrigerator even if it requires a forced save and use within 24 hours. By blending 3) aminoglycosides and (tobramycin, etc.), and so leads to reduced activity of the aminoglycoside antibiotics, and be administered by different routes each when used in combination with this drug. that 4) residual liquid is not used in any way. (3) intravenous administration: It can be used to warm the body temperature of the solution 1) cold season. The 2) intravenous administration, because they may cause vascular pain, phlebitis or thrombosis, slowing the careful injection site, the injection method and the like, as much as possible the injection rate. Note 10. Other Upon administration of (1) this drug, be carried out blood tests, liver function tests, etc. on a regular basis is desirable. It has been reported that the incidence of hypersensitivity symptoms of this drug is higher in patients with cystic fibrosis (2) foreign. It has been reported (3) combination, and prolong the muscle relaxant effect of vecuronium.
更新日期: 2014-09-11
附件:
 
调控比例: 100%
订购表单下载
Copyrights © 2010,2011,2012 www.ShiJieBiaoPin.com, Inc., All rights Reserved www.ShiJieBiaoPin.com, Inc.
客服工作时间:太平洋时间18:00-24:00
国内客服电话:     国际免费电话:
友情提示:以上电话为免费电话,无需您承担任何费用,世界标品提供中文客服,请您放心拨打!
电子邮箱:sciteck.hongkong@gmail.com, 15901965168@163.com